Azenta, Inc. (AZTA)
NASDAQ: AZTA · Real-Time Price · USD
16.81
-0.22 (-1.29%)
May 14, 2026, 3:49 PM EDT - Market open
Azenta Revenue
Azenta had revenue of $144.80M in the quarter ending March 31, 2026, with 1.02% growth. This brings the company's revenue in the last twelve months to $596.33M, up 1.74% year-over-year. In the fiscal year ending September 30, 2025, Azenta had annual revenue of $593.82M with 3.55% growth.
Revenue (ttm)
$596.33M
Revenue Growth
+1.74%
P/S Ratio
1.34
Revenue / Employee
$198,828
Employees
3,000
Market Cap
774.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 593.82M | 20.37M | 3.55% |
| Sep 30, 2024 | 573.45M | 21.96M | 3.98% |
| Sep 30, 2023 | 551.49M | -4.01M | -0.72% |
| Sep 30, 2022 | 555.50M | 41.80M | 8.14% |
| Sep 30, 2021 | 513.70M | 125.17M | 32.21% |
| Sep 30, 2020 | 388.54M | -392.31M | -50.24% |
| Sep 30, 2019 | 780.85M | 149.29M | 23.64% |
| Sep 30, 2018 | 631.56M | 104.06M | 19.73% |
| Sep 30, 2017 | 527.50M | 93.49M | 21.54% |
| Sep 30, 2016 | 434.01M | -118.70M | -21.48% |
| Sep 30, 2015 | 552.71M | 69.86M | 14.47% |
| Sep 30, 2014 | 482.85M | 60.41M | 14.30% |
| Sep 30, 2013 | 422.44M | -66.54M | -13.61% |
| Sep 30, 2012 | 488.98M | -199.12M | -28.94% |
| Sep 30, 2011 | 688.11M | 95.13M | 16.04% |
| Sep 30, 2010 | 592.97M | 374.27M | 171.13% |
| Sep 30, 2009 | 218.71M | -307.66M | -58.45% |
| Sep 30, 2008 | 526.37M | -216.89M | -29.18% |
| Sep 30, 2007 | 743.26M | 135.76M | 22.35% |
| Sep 30, 2006 | 607.49M | 237.72M | 64.29% |
| Sep 30, 2005 | 369.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| AtriCure | 552.16M |
| AngioDynamics | 313.73M |
| STAAR Surgical Company | 290.38M |
| LeMaitre Vascular | 256.28M |
| BioLife Solutions | 101.66M |
| Kestra Medical Technologies | 83.72M |
| Alamar Biosciences | 74.21M |
AZTA News
- 7 days ago - Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 8 days ago - Azenta Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029 - PRNewsWire
- 14 days ago - Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast - PRNewsWire
- 5 weeks ago - Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution - PRNewsWire
- 5 weeks ago - Azenta price target lowered to $35 from $45 at Evercore ISI - TheFly
- 6 weeks ago - Azenta price target lowered to $35 from $40 at Jefferies - TheFly
- 2 months ago - Azenta Transcript: M&A announcement - Transcripts